Viral warts. Viral warts
Conditions
Interventions
Intervention 1: For the intervention group 0.1 mL intralesional MMR vaccine made by Razi institute will be injected. Intervention 2: For the control group 0.3 mL intralesional normal saline will be in
Treatment - Drugs
Placebo
For the intervention group 0.1 mL intralesional MMR vaccine made by Razi institute will be injected
For the control group 0.3 mL intralesional normal saline will be injected.
Sponsors
Vice chancellor for Research of Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients with Palmoplantar warts Exclusion criteria: Acute febrile disease; treatment of warts within last month; History of allergic reaction to MMR vaccine; asthma; history of allergic skin disease such as eczema and hives, meningitis, seizure, primary or iatrogenic immunodeficiency; pregnancy; lactation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wart size. Timepoint: 0-2-4-6-8-10 Weeks. Method of measurement: Wart observation.;Number of warts. Timepoint: 0-2-4-6-8-10 Weeks. Method of measurement: Observation.;Size of other lesions. Timepoint: 0-2-4-6-8-10 Weeks. Method of measurement: Observation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Injection pain. Timepoint: 0-2-4-6-8-10 weeks. Method of measurement: yes-no.;Recurrency. Timepoint: 0-1-2-3-4-5-6 months. Method of measurement: yes-no. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGhasem Ramatpour Rokni, MD
Mazandaran University of Medical Sciences
Outcome results
None listed